C-reactive protein as a prognostic marker in chronic obstructive pulmonary disease

Experimental and Therapeutic Medicine

Volumn 7, Issue 2, 2014, Pages 443-446

  Deng, Zai Chun ^a   Zhao, Peng ^b   Cao, Chao ^a   Sun, Shi Fang ^a   Zhao, Feng ^a   Lu, Chao Yue ^a   Ma, Hong Ying ^a  

^a NINGBO UNIVERSITY   (China)

^b People's Hospital of Haining   (China)

Author keywords

C reactive protein; Chronic obstructive pulmonary disease; Survival

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PROSPECTIVE STUDY; SURVIVAL;

EID: 84890515654     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.1441     Document Type: Article

References (24)

1. Murray CJ and Lopez AD: Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 349: 1269-1276, 1997.
2. Karadag F, Kirdar S, Karul AB and Ceylan E: The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease. Eur J Intern Med 19: 104-108, 2008.
3. He Z, Chen Y, Chen P, Wu G and Cai S: Local inflammation occurs before systemic inflammation in patients with COPD. Respirology 15: 478-484, 2010.
4. Man SF, Connett JE, Anthonisen NR, Wise RA, Tashkin DP and Sin DD: C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 61: 849-853, 2006.
5. Waschki B, Kirsten A, Holz O, et al: Physical activity is the strongest predictor of all-cause mortality in patients with chronic obstructive pulmonary disease: a prospective cohort study. Chest 140: 331-342, 2011.
6. Celli BR, Cote CG, Marin JM, et al: The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 350: 1005-1012, 2004.
7. Stolz D, Christ-Crain M, Morgenthaler NG, et al: Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 131: 1058-1067, 2007.
8. Murphy SA, Haja Mydin H, Fatah S and Antunes G: Predicting end-of-life in patients with an exacerbation of COPD by routine clinical assessment. Respir Med 104: 1668-1674, 2010.
9. Lacoma A, Prat C, Andreo F, et al: Value of procalcitonin, C-reactive protein, and neopterin in exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 6: 157-169, 2011.
10. de Torres JP, Pinto-Plata V, Casanova C, et al: C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest 133: 1336-1343, 2008.
11. Liu SF, Wang CC, Chin CH, Chen YC and Lin MC: High value of combined serum C-reactive protein and BODE score for mortality prediction in patients with stable COPD. Arch Bronconeumol 47: 427-432, 2011.
12. Miniati M, Monti S, Bottai M, Cocci F, Fornai E and Lubrano V: Prognostic value of C-reactive protein in chronic obstructive pulmonary disease. Intern Emerg Med 6: 423-430, 2011.
13. Man SF, Xing L, Connett JE, et al: Circulating fibronectin to C-reactive protein ratio and mortality: a biomarker in COPD? Eur Respir J 32: 1451-1457, 2008.
14. Rabe KF, Hurd S, Anzueto A, et al: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176: 532-555, 2007.
15. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A and Nordestgaard BG: C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175: 250-255, 2007.
16. Cao C, Fang JJ, Ying T, et al: Vascular endothelial growth factor +936C/T and +405G/C polymorphisms and cancer risk: a meta-analysis. Arch Med Res 41: 548-557, 2010.
17. Cao C, Ying T, Fang JJ, et al: Polymorphism of vascular endothelial growth factor -2578C/A with cancer risk: evidence from 11263 subjects. Med Oncol 28: 1169-1175, 2011.
18. Parmar MK, Torri V and Stewart L: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17: 2815-2834, 1998.
19. Prescott E, Almdal T, Mikkelsen KL, Tofteng CL, Vestbo J and Lange P: Prognostic value of weight change in chronic obstructive pulmonary disease: results from the Copenhagen City Heart Study. Eur Respir J 20: 539-544, 2002.
20. Schembri S, Anderson W, Morant S, et al: A predictive model of hospitalization and death from chronic obstructive pulmonary disease. Respir Med 103: 1461-1467, 2009.
21. Coxson HO, Chan IH, Mayo JR, Hlynsky J, Nakano Y and Birmingham CL: Early emphysema in patients with anorexia nervosa. Am J Respir Crit Care Med 170: 748-752, 2004.
22. Cao C, Wang R, Wang J, Bunjhoo H, Xu Y and Xiong W: Body mass index and mortality in chronic obstructive pulmonary disease: a meta-analysis. PLoS One 7: e43892, 2012.
23. Nizet TA, van den Elshout FJ, Heijdra YF, van de Ven MJ, Mulder PG and Folgering HT: Survival of chronic hypercapnic COPD patients is predicted by smoking habits, comorbidity, and hypoxemia. Chest 127: 1904-1910, 2005.
24. Nishimura K, Izumi T, Tsukino M and Oga T: Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 121: 1434-1440, 2002.